Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
REGN
REGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REGN News
Trump Announces US-Iran Deal, Market Rallies
4d ago
CNBC
Sensorion Selects SENS-601 as Lead Program for Hearing Loss Treatment
Jun 10 2026
NASDAQ.COM
Pomerantz LLP Investigates Regeneron for Securities Fraud
Jun 09 2026
Globenewswire
Parabilis Medicines Plans $476M IPO Amid Regeneron Collaboration
Jun 04 2026
seekingalpha
CytomX Expands Collaboration with Regeneron Worth Up to $4B
Jun 03 2026
seekingalpha
Pomerantz LLP Investigates Regeneron for Securities Fraud
Jun 02 2026
Globenewswire
WHO Recommends Maftivimab for Ebola Treatment Evaluation
May 29 2026
NASDAQ.COM
WHO Approves Evaluation of Regeneron's Antibody for Ebola Treatment
May 28 2026
seekingalpha
Regeneron Recommends Maftivimab for Ebola Treatment Trials
May 28 2026
Yahoo Finance
Commvault and Others Under Shareholder Investigation
May 27 2026
Globenewswire
Multiple Companies Under Shareholder Investigation
May 26 2026
Globenewswire
Regeneron Enters $2.32 Billion Collaboration with Parabilis for Undruggable Proteins
May 25 2026
Yahoo Finance
Biotech Sector Regulatory Approvals and Collaborations
May 22 2026
NASDAQ.COM
Regeneron Reports Positive Phase 1/2 Results for Lynozyfic in AL Amyloidosis Treatment
May 22 2026
NASDAQ.COM
Regeneron's Otarmeni Accepted for EU Accelerated Review
May 22 2026
NASDAQ.COM
Regeneron Receives EMA Accelerated Review for Otarmeni
May 22 2026
Newsfilter
Show More News
